Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer

Plain-language summary

This study investigates a multiplex mutation detection system using mass spectrometry in bladder cancer. Patients aged 18 and over with histologically confirmed urothelial carcinoma of the bladder and sufficient tumor tissue available can take part. It is a study without an assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Zhilong Dong

Intervention

Multiplex Mutation Detection System for Bladder Cancer (Nucleic Acid Mass Spectrometry)

Start date

2/25/2026

Estimated completion

7/1/2028

Countries

China

Related genes

Locations

• Lanzhou, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Histologically confirmed diagnosis of urothelial carcinoma of the bladder (any stage, including non-muscle invasive and muscle invasive).

   \-
2. Availability of sufficient tumor tissue specimen (fresh frozen) for DNA extraction and mutation analysis.

   \-
3. Age ≥ 18 years at time of diagnosis.

Exclusion Criteria:

1. History of other malignant tumors within the past 5 years, except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix.

   \-
2. Inadequate quality or quantity of tumor tissue DNA for mutation panel analysis (e.g., severe DNA degradation, insufficient DNA yield).

   \-
3. Pregnancy or breastfeeding.

   \-
4. Serious uncontrolled intercurrent illness that would interfere with study follow-up or compliance, including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.